U.S. stock night market volatility: NOVARTIS AG's risk resistance capability recognized, stock price rises 3% in night trading

U.S. Stock Night Market Movements Novartis AG rose 3.00% in the night market. Based on recent news, On December 28, Novartis AG demonstrated strong risk resistance due to its diversified product line in the face of regulatory risks, gaining market recognition for its stability, which drove the stock price up. The pharmaceutical industry overall performed steadily, with investors favoring stability. Stocks with High Trading Volume in the Industry Novo Nordisk fell 1.03%. Based on recent key news: On December 27, Novo Nordisk and Eli Lilly initiated a price reduction wave, with actual transaction prices nearly halved. This move aims to respond to market competition ahead of the patent expiration of semaglutide, affecting the stock price decline. (Cailian Press) On December 27, the review progress of the oral version of semaglutide for weight loss indications in China was not disclosed, intensifying the competition in the development of domestic biosimilars, affecting stock price volatility. (Cailian Press) On December 27, Novo Nordisk's long-acting growth hormone Nozov® was approved for market launch, marking further expansion in the Chinese market, stabilizing the stock price. (Cailian Press) The competition in the GLP-1 market is intensifying, with ample space for domestic alternatives. Eli Lilly rose 0.21% in the night market. Based on recent key news: On December 27, Eli Lilly and Novo Nordisk initiated a price reduction wave, with actual transaction prices nearly "halved" compared to six months ago, in response to the patent expiration of semaglutide and competition from domestic innovative drugs and biosimilars. This move aims to establish a defensive high wall by setting price anchor points. (Cailian Press) On December 27, Eli Lilly's tri-target GLP-1 new drug retatrutide achieved a weight loss effect of 29% in clinical trials, surpassing the performance of tirzepatide, demonstrating strong market competitiveness. (Cailian Press) On December 26, Eli Lilly signed a cooperation agreement worth $260.2 million with ABL Bio to promote joint research based on a bispecific antibody platform, further consolidating its leading position in the biotechnology field. (MT Newswires) The GLP-1 market has huge potential, with increasing competition. Pfizer fell 0.12% in the night market. Based on recent news, On December 26, MarketBeat pointed out that Pfizer was not included in the list of five stocks recommended by top analysts, despite its rating being hold. This indicates a lack of market confidence in Pfizer, leading to pressure on the stock price. On December 28, analysts suggested investors consider Pfizer for medium-term swing trading, based on its support and resistance levels for the fourth quarter. However, performance in the coming years may be disappointing, further exacerbating market caution. On December 29, some analysts predicted that Pfizer's total shareholder return would underperform the S&P 500 index and gave a strong sell rating. This negative outlook has created significant downward pressure on the stock price. The market remains cautious about Pfizer's future performance, with active trading volume